Loading...
XASX
BTC
Market cap12mUSD
Dec 04, Last price  
0.06AUD
1D
1.64%
1Q
-4.62%
Jan 2017
-46.09%
IPO
-85.31%
Name

BTC Health Ltd

Chart & Performance

D1W1MN
XASX:BTC chart
P/E
18.22
P/S
1,175.02
EPS
0.00
Div Yield, %
Shrs. gr., 5y
18.59%
Rev. gr., 5y
-44.75%
Revenues
16k
+23.38%
020,00013,0002,000000037,71215,59611,35071,18428,496207,837317,763169,60419,19095,00413,26016,360
Net income
1m
P
-1,161,000-367,000-759,000-7,386,000-4,333,000-5,707,000-3,495,000-1,860,167-501,748-1,888,973-507,019-170,780-516,530-1,467,834-692,742-283,036-391,686-576,076-10,167,8621,055,000
CFO
-405k
L-6.65%
00000000-422,931-145,675-209,529-162,700-388,366-555,524-655,800-492,023-366,152-392,911-433,608-404,757
Dividend
Oct 19, 20120.01 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia. The fund invests in both listed and unlisted companies.
IPO date
Aug 29, 2000
Employees
1
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT